The European Association of Urology (EAU) “Update on Prostate Cancer” meeting was held in Vienna, Austria, on Friday and Saturday, and Dr. Zachary Klaassen was again busy providing summary reports on presentations for UroToday. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: active surveillance, Diagnosis, PSA, screening, staging, testing | Leave a comment »
Yesterday we mentioned a new paper on PSA screening by Tsodikov et al. in the Annals of Internal Medicine. We have now had the chance to read the full text of that paper, as well as the associated editorial by Vickers in the same issue of the journal. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: mortality, PSA, risk, screening, testing | 5 Comments »
A new article just published in the Annals of Internal Medicine has suggested that PSA testing really does save lives. But the new article isn’t based on any really new data. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: PSA, screening, testing | Leave a comment »
Your sitemaster has long believed that, while electronic and other decision aids can be helpful in providing men with information and education about prostate cancer, their value in helping them to make the best decisions is less clear. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: aid, decision, decision-making, PSA, screening, test | 3 Comments »
To quote the abstract of the paper discussed below, the use of the PSA test to screen for risk of prostate cancer “in men at normal risk of prostate cancer is one of the most contested issues in cancer screening.” No! Really? … READ MORE …
Filed under: Diagnosis, Risk | Tagged: benefit, diagosis, PSA, risk, screening, testing | 3 Comments »
A newly published study in Clinical Cancer Research has implied the potential development of a completely new and much more accurate way to be able to identify risk for metastatic prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: blood, cell, circulating, count, CTC, megakaryocyte, PSA, tumor | 1 Comment »
Dr. Michael Barry has been a long-time advocate for caution in the appropriate use of PSA testing and for awareness of the risks of over-treatment of low-risk forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, Diagnosis, PSA, risk, screening, surveillance, testing | Leave a comment »
Whatever one may happen to think about the value of the PSA test, we all know that it is very bad at actually telling a doctor or a patient if that patient is at real risk for clinically significant prostate cancer. So, from that perspective … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, evaluation, MRI, PSA, research, risk, work-up | 2 Comments »
A newly published study in the journal Urology (the “Gold Journal”) has suggested that — at least for patients with a PSA level between 4 and 10 ng/ml — PSA density may be better than PSA level in the determination of which of these patients need to go on to have a biopsy. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, density, Diagnosis, PSA, risk | 7 Comments »
As indicated earlier this morning, the US Preventive Services Task Force (USPSTF) has issued new draft guidance on screening for risk of prostate cancer. Access to all the relevant details is provided below: … READ MORE …
Filed under: Diagnosis, Risk | Tagged: guidance, PSA, screening, testing, USPSTF | 17 Comments »
As yet we have not seen the details, but, according to a report on National Public Radio early this morning, the US Preventive Services Task Force (USPSTF) has stated that men up to age 70 should discuss the risk and benefits of PSA testing with their doctors and then make individual decisions about whether to get tested. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: PSA, risk, screening, testing, USPSTF | 4 Comments »
A report on the HealthDay web site related to a presentation about the role of MRI scanning in the diagnosis of localized prostate cancer seems to demonstrate a significant division of views about the value of standardized use of mpMRI in the diagnosis of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, MRI, PSA, risk, screening, testing | 1 Comment »
A presentation at the ongoing annual meeting of the European Association of Urology (EAU), in London, England, has reported (perhaps unsurprisingly) that PSA testing for risk of prostate cancer based on family history alone is not a very good idea. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Diagnosis, family, history, PSA, risk, testing | 1 Comment »
A new analysis of a large data set compiled by Kaiser Permanente suggests that combining PSA data with genetic risk data may offer a much more effective way to assess risk for clinically significant prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: genomics, gentics, Management, PSA, risk, strategy | 8 Comments »
So a relatively new article in Reviews in Urology caught your Sitemaster’s eye this morning — and worried him because it seemed to be communicating a conclusion of questionable accuracy, which we will explore below. And if we have misinterpreted the data provide in the paper, we are more than willing to be corrected. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biopsy, elderly, Gleason score, PSA, risk, stage, Treatment | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 